Abstract

Alcohol currently contributes to 5% of the overall global burden of diseases and injuries. Alcohol consumption results in death and disability at young age. Medicinal products approved for treatment of alcohol dependence syndrome include disulfiram, Naltrexone, Cyanamid and nalmefene. Variability of a patient-to-patient pharmacotherapy therapeutic effect can also be associated with genetic causes. Examination of the system of pharmacogenetic markers in narcology will be used to provide for preliminary prognosis of effectiveness and tolerance of medicinal products during personalized anti-relapse (supporting) therapy to support and prolong remission in patients with alcohol dependence.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.